Among those with metastatic NSCLC, patients were eligible to enroll if they had metastatic NSCLC without an actionable EGFR mutation or ALK/ROS1 rearrangement or if they had an actionable EGFR mutation or ALK/ROS1 rearrangement but developed oligoprogression after treatment with a first-line tyrosine kinase inhibitor. Here, ROS1 is linked to non-small cell lung carcinoma.